Who Are the Core Customers of Veracyte Company?

Pulmonologists, endocrinologists, urologists, and pathologists form the core: they order Afirma, Decipher, Envisia, and Percepta to resolve indeterminate biopsies and guide treatment. In 2025, Veracyte customers in these specialties accounted for the majority of test volume, with >60% of revenue tied to clinical diagnostic platforms.

Integrated Delivery Networks (IDNs), academic medical centers, and pathology laboratories using Veracyte tests are key secondary buyers; in 2025 IDNs represented a growing share of contracts and adoption. The 2026 pivot to decentralized testing adds international pathology labs running assays on the nCounter system as an expanding customer segment.

Veracyte serves businesses and institutions-hospitals, specialty clinics, and clinical labs-rather than direct consumers; clinicians and institutional lab managers are the buyers. Payers and insurers influence uptake through coverage decisions, while referring primary care physicians drive test referrals to specialists.

The thyroid market using Afirma remains the single largest commercial segment in 2025, followed by Decipher for prostate cancer and pulmonary offerings (Envisia, Percepta). Academic medical centers and large IDNs accounted for a disproportionate share of commercial contracts, and the 2026 decentralized-testing push targets pathology laboratories internationally to increase assay-capable sites.

Veracyte customers concentrate in academic medical centers and large hospital systems in the Northeast and West Coast where specialty oncology, endocrinology, and pathology services are dense; these regions generate roughly ~80% of revenue in recent fiscal cycles.

International growth is strongest in EMEA and Asia-Pacific, led by adoption of the Decipher prostate test and a shift to decentralized, kit-based workflows that enable pathology labs using Veracyte tests and hospitals and clinics that partner with Veracyte to scale diagnostics.

Veracyte is strongest in test categories tied to oncology and endocrine referral pathways-Afirma for thyroid and Decipher for prostate-reflected in higher per-test reimbursement and strong usage among oncologists and endocrinologists as Veracyte customers, and in partnerships with academic medical centers and clinical laboratories providing Veracyte test services.

In 2025, lung cancer diagnostics surged due to expanded global screening and a rising clinical burden of interstitial lung diseases; the underserved ILD market is estimated at $500,000,000 annually, and oncology practices using Veracyte for lung cancer diagnostics and pulmonologists ordering Veracyte bronchial genomic tests are accelerating demand. See more on distribution and customer acquisition in Customer Acquisition of Veracyte Company.

Veracyte grows its Veracyte target market by adding complementary platforms such as the C2i Genomics minimal residual disease offering, entering the >$1 billion MRD monitoring market to reach oncology practices, academic medical centers, and international healthcare systems using Veracyte.

By limiting menu expansion to genomic tests where complexity justifies premium pricing, Veracyte preserves its brand with pathology labs using Veracyte tests, pulmonologists, endocrinologists, and healthcare providers using Veracyte who rely on validated classifiers.

Repeat demand rises as clinicians order sequential monitoring and diagnostic panels; lifetime value per patient increases with MRD and chronic immunology follow-up, boosting renewals among hospitals and clinics that partner with Veracyte and pathology laboratories that adopt Veracyte genomic classifiers.

Scale of decentralized labs and targeted acquisitions drive growth: in 2026 Veracyte sustains 65 percent to 70 percent non-GAAP gross margins on core domestic lab services while capturing international volume, and MRD expands per-patient revenue - the largest lever for increasing Veracyte customers and keeping oncologists and endocrinologists as Veracyte customers.